Identification of biomarkers that can predict cognitive decline is of utmost importance for advance in dementia pharmacotherapy. In this study, cerebral blood flow (CBF) is investigated as a predictor for cognitive decline in a healthy aging population. We found CBF in the frontal lobe to be most predictive for cognitive decline, specifically for episodic memory and in the older population. This suggest that CBF can be used as a biomarker to identify subjects susceptible to cognitive decline, to identify suitable cohorts for clinical trials, and to monitor the effects of pharmacotherapy.
This abstract and the presentation materials are available to members only; a login is required.